Category Archives: Guest Blog

Industry Challenged: “Do More for Teenagers with Cancer”

By Leela Barham. Accessing the latest cancer drugs always seem to be controversial. Not just because of the money but also because of the complexities of accessing treatments during their development. This seems to be especially the case for young people with cancer, according to the UK’s Teenage Cancer Trust. 
Also posted in Europe, Global, R&D | Tagged , , , | Leave a comment

Value-Based Assessment in the UK: The Industry View

By Leela Barham. In the UK, Value-Based Pricing (VBP) has morphed into Value-Based Assessment (VBA), with the National Institute for Health and Care Excellence (NICE) tasked with taking the loose policy concepts (established as far back as 2010) and actually implementing them. Earlier this year, NICE set out its approach, which boiled down to taking a […]
Also posted in Europe, Global, pricing, Regulatory | Tagged , , , , , , | Leave a comment

Show Me the Money: First New PPRS Payments in UK

By Leela Barham. The Pharmaceutical Price Regulation Scheme (PPRS) is a long-standing scheme where the pharmaceutical industry, represented by the Association of the British Pharmaceutical Industry (ABPI), negotiates with the Department of Health (DH) to agree how to indirectly manage the price of branded medicines. Its latest incarnation includes a brand new feature. Instead of […]
Also posted in Europe, Global, Op-Ed, pricing | Tagged , , , , | Leave a comment

Mastering the Language of Payers

By Sydney Rubin. The first rule of effective communications — whether speaking to a beloved offspring or an important customer — is to know your audience. We must understanding what motivates the listener, what they care about, what language will most likely persuade. Don’t expect an argument on the importance of retirement savings to convince […]
Also posted in Marketing, Op-Ed | Tagged , , , | Leave a comment

Making the Most of Social Media (Within FDA’s New Guidelines)

By Ken Ribotsky. Pharmaceutical companies have begun using social media for business needs and promotion, yet have been hesitant to become too engaged since the FDA’s stance on social media activity remained unclear. But now that we know the FDA’s specific guidelines for pharma companies’ actions online, it’s time for brands to consider diving into […]
Also posted in compliance, E-Media, FDA, Op-Ed, Regulatory, social media | Tagged , | 1 Comment
  • Categories

  • Meta